# A Trial of SHR-2017 Injection in Patients With Bone Metastases From Solid Tumors

Source: https://onco.cc/trials/nct07028268/  
OnCo record `nct07028268` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Denosumab in advanced solid tumours, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.

## Summary

A Trial of SHR-2017 Injection in Patients With Bone Metastases From Solid Tumors is a phase 2 interventional study registered as NCT07028268 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 210 participants planned, started 2025-06-24 and due to reach its primary completion in 2025-12. Interventions recorded: SHR-2017、Denosumab placebo and Denosumab；SHR-2017 placebo.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07028268
- Phase: 2
- Setting: A Multicenter, Randomized, Double-Blind, Positively Controlled Phase II Clinical Study Evaluating the Efficacy and Safety of SHR-2017 Injection in Patients With Bone Metastases From Solid Tumors
- Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Enrolled: 210

## Sources

- ClinicalTrials.gov NCT07028268: https://clinicaltrials.gov/study/NCT07028268

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Denosumab](https://onco.cc/drugs/denosumab/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct07028268.json